The information contained on this website is only a summary of the information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses. Because this website is just a summary, you should review the Notice for additional details.

Summary of the Action and Settlement

This website relates to securities class action (the "Action") brought by investors alleging that Boston Scientific Corporation ("Boston Scientific") and certain of its executives, Michael F. Mahoney, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Joseph M. Fitzgerald, Kevin Ballinger, and Susan Vissers Lisa (collectively, the “Individual Defendants”) violated the federal securities laws by making false and misleading statements regarding Boston Scientific’s Lotus Edge medical device. If the Court approves the proposed Settlement, the Action will be dismissed, and members of the Settlement Class will settle and release all Released Plaintiffs’ Claims.

The Court-appointed Lead Plaintiff, Union Asset Management Holding AG (“Lead Plaintiff”) have settled the Action with Defendants for $38,500,000 in cash (the “Settlement”). On April 23, 2024, the Court entered a final Judgment approving the Settlement and orders approving the Plan of Allocation and awarding attorneys’ fees and litigation expenses.If you are a member of the Settlement Class, you are subject to the Settlement. The Settlement Class consists of:   

all persons or entities who purchased or otherwise acquired Boston Scientific common stock during the period from September 16, 2020 through November 16, 2020, inclusive, and were damaged thereby.

Excluded from the Settlement Class are: (i) Defendants; (ii) Immediate Family Members of any Individual Defendant; (iii) any person who was an Officer or director of Boston Scientific during the Class Period and any of their Immediate Family Members; (iv) any parent, subsidiary, or affiliate of Boston Scientific; (v) any firm, trust, corporation, or other entity in which any Defendant or any other excluded person or entity has, or had during the Class Period, a controlling interest; and (vi) the legal representatives, agents, affiliates, heirs, successors-in-interest, or assigns of any such excluded persons or entities.  Also excluded from the Settlement Class are any persons or entities who or which excluded themselves by submitting a request for exclusion.

Please read the Notice to fully understand your rights and options. A copy of the Notice can be found in the menu at the top of this page.

The claims administration has been completed as of February 7, 2025. 

On February 14, 2025, Lead Counsel filed an Unopposed Motion for Approval of Distribution Plan. On February 26, 2025, the Court approved that motion. The initial distribution of the net settlement fund is expected to occur in April or May 2025.

Please continue to check this website for further updates.

How do I obtain more information?

Detailed information about the Settlement is contained in the Notice, a copy of which can be found in the menu at the top of this page. Additional information can also be obtained by contacting the Claims Administrator by calling toll-free (877) 595-0084 or emailing info@BostonScientificSecuritiesLitigation.com or mailing a letter to:

Boston Scientific Securities Litigation
c/o JND Legal Administration
P.O. Box 91477
Seattle, WA 98111

Inquiries should NOT be directed to the Court or the Clerk of the Court.